Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Touchstone Innovations PLC       GB00B170L953

TOUCHSTONE INNOVATIONS PLC

SummaryChartsNewsCompany 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Touchstone Innovations : Portfolio company TopiVert demonstrates proof of concept in Phase I/IIa study of TOP1630 in the treatment of dry eye syndrome

11/28/2017 | 09:23am EST

Portfolio company TopiVert Pharma Limited ('TopiVert' or the 'Company') has today announced successful results from the Company's Phase I/II a proof of concept study of its wholly-owned TOP1630 ophthalmic solution in the treatment of dry eye syndrome (DES).

TopiVert is a clinical-stage biotechnology company developing Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, locally-acting, medicines for the treatment of chronic inflammatory gastrointestinal (GI) and ocular diseases. NSKIs target key kinases in the signalling cascade in inflammatory cells, leading to synergistic inhibition of pathways involved in innate and adaptive immunities.

TOP1630, is the Company's lead NSKI for ophthalmology. The product is locally absorbed and retained in target inflammatory cells in the cornea and conjunctiva when administered as eye drops, and with only minimal systemic exposure, it is an ideal topical eye therapy.

In the study TOP1630 delivered statistically significant results across multiple signs and symptoms endpoints in DES. Furthermore, TOP1630 demonstrated excellent safety and placebo-like tolerability and comfort profiles.

Ajay Duggal, TopiVert's Chief Medical Officer, commented:

'TOP1630 has delivered compelling data in a Phase I/IIa proof of concept study for the treatment of dry eye syndrome. We believe that the consistency of effect demonstrated across a range of sign and symptom endpoints, coupled with the placebo-like tolerability profile, sets a new benchmark for DES treatments.'

See the full TopiVert statement here

Touchstone Innovations plc published this content on 28 November 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 28 November 2017 14:22:02 UTC.


© Publicnow 2017
All news about TOUCHSTONE INNOVATIONS PLC
2017TOUCHSTONE INNOVATIONS : Ieso Digital Health named as one of the UK's top 10 Dis..
PU
2017TOUCHSTONE INNOVATIONS : Portfolio company TopiVert demonstrates proof of concep..
PU
2017TOUCHSTONE INNOVATIONS : Exercise of share options
PU
2017TOUCHSTONE INNOVATIONS : Issue of Equity
PU
2017TOUCHSTONE INNOVATIONS : Board changes following cancellation of admission
PU
2017TOUCHSTONE INNOVATIONS : Posting of Annual Report
PU
2017TOUCHSTONE INNOVATIONS : Offer Update; Appointment of Prof. David Begg
PU
2017TOUCHSTONE INNOVATIONS : Updated recommendation by Touchstone Innovations
PU
2017TOUCHSTONE INNOVATIONS : Offer Update - Wholly Unconditional
PU
2017TOUCHSTONE INNOVATIONS : Grant of share options
PU
More news
Chart TOUCHSTONE INNOVATIONS PLC
Duration : Period :
Touchstone Innovations PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
David Graham Baynes Director
Gregory Simon Smith Director
Michael Charles Nettleton Townend Director
Angela Leach Secretary
Kelsey Bircher Lynn Skinner Director-Technology Ventures
Sector and Competitors
1st jan.Capitalization (M$)
TOUCHSTONE INNOVATIONS PLC-11.17%0
CINTAS CORPORATION34.19%37 779
UNITED RENTALS39.66%16 801
EDENRED5.57%14 304
BUREAU VERITAS SA-7.39%11 561
GENPACT LIMITED-2.51%7 784